Mass spectrometry-based chemical mapping and profiling toward molecular understanding of diseases in precision medicine. Issue 23 (25th May 2021)

• Record Type: Journal Article
• Authors: Hu, Yechen; Wang, Zhongcheng; Liu, Liang; Zhu, Jianhua; Zhang, Dongxue; Xu, Mengying; Zhang, Yuanyuan; Xu, Feifei; Chen, Yun
• Is Part Of: Chemical science. Volume 12:Issue 23(2021)
• Page Start: 7993
• Page End: 8009
• Publication Date: 2021-05-25
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d1sc00271f
• Languages: English
• ISSNs: 2041-6520

Abstract

Abstract : An overview of MS-based chemical mapping and profiling, indicating its contributions to the molecular understanding of diseases in precision medicine by answering "what", "where", "how many" and "whose" chemicals underlying clinical phenotypes. Abstract : Precision medicine has been strongly promoted in recent years. It is used in clinical management for classifying diseases at the molecular level and for selecting the most appropriate drugs or treatments to maximize efficacy and minimize adverse effects. In precision medicine, an in-depth molecular understanding of diseases is of great importance. Therefore, in the last few years, much attention has been given to translating data generated at the molecular level into clinically relevant information. However, current developments in this field lack orderly implementation. For example, high-quality chemical research is not well integrated into clinical practice, especially in the early phase, leading to a lack of understanding in the clinic of the chemistry underlying diseases. In recent years, mass spectrometry (MS) has enabled significant innovations and advances in chemical research. As reported, this technique has shown promise in chemical mapping and profiling for answering "what", "where", "how many" and "whose" chemicals underlie the clinical phenotypes, which are assessed by biochemical profiling, MS imaging, molecular targeting and probing, biomarker grading disease classification, etc. These features can potentially enhance the precision of disease diagnosis, monitoring and treatment and thus further transform medicine. For instance, comprehensive MS-based biochemical profiling of ovarian tumors was performed, and the results revealed a number of molecular insights into the pathways and processes that drive ovarian cancer biology and the ways that these pathways are altered in correspondence with clinical phenotypes. Another study demonstrated that quantitative biomarker mapping can be predictive of responses to immunotherapy and of survival in the supposedly homogeneous group of breast cancer patients, allowing for stratification of patients. In this context, our article attempts to provide an overview of MS-based chemical mapping and profiling, and a perspective on their clinical utility to improve the molecular understanding of diseases for advancing precision medicine.